RU2020121533A - Антагонисты ildr2 и их комбинации - Google Patents

Антагонисты ildr2 и их комбинации Download PDF

Info

Publication number
RU2020121533A
RU2020121533A RU2020121533A RU2020121533A RU2020121533A RU 2020121533 A RU2020121533 A RU 2020121533A RU 2020121533 A RU2020121533 A RU 2020121533A RU 2020121533 A RU2020121533 A RU 2020121533A RU 2020121533 A RU2020121533 A RU 2020121533A
Authority
RU
Russia
Prior art keywords
ildr2
antibody
seq
fragment
derivative
Prior art date
Application number
RU2020121533A
Other languages
English (en)
Russian (ru)
Inventor
Ларс РЕЗЕ
Уве ГРИТЦАН
Юлиа ХЮТТЕР
Спенсер ЛИАНГ
Эндрю ПАУ
Джон ХАНТЕР
Офер ЛЕВИ
Илан Вакнин
Original Assignee
Байер Акциенгезельшафт
Байер Фарма Акциенгезельшафт
Компуджен Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Акциенгезельшафт, Байер Фарма Акциенгезельшафт, Компуджен Лтд. filed Critical Байер Акциенгезельшафт
Publication of RU2020121533A publication Critical patent/RU2020121533A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2020121533A 2017-11-30 2018-11-28 Антагонисты ildr2 и их комбинации RU2020121533A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592913P 2017-11-30 2017-11-30
US62/592,913 2017-11-30
PCT/EP2018/082779 WO2019105972A1 (en) 2017-11-30 2018-11-28 Ildr2 antagonists and combinations thereof

Publications (1)

Publication Number Publication Date
RU2020121533A true RU2020121533A (ru) 2021-12-30

Family

ID=64559680

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020121533A RU2020121533A (ru) 2017-11-30 2018-11-28 Антагонисты ildr2 и их комбинации

Country Status (16)

Country Link
US (1) US11655297B2 (https=)
EP (1) EP3717007B1 (https=)
JP (1) JP7350740B2 (https=)
KR (1) KR20200096223A (https=)
CN (1) CN111655287B (https=)
AR (1) AR113850A1 (https=)
AU (1) AU2018376231A1 (https=)
BR (1) BR112020010767A2 (https=)
CA (1) CA3083675A1 (https=)
IL (1) IL274751B2 (https=)
MX (1) MX2020005483A (https=)
PE (1) PE20200956A1 (https=)
RU (1) RU2020121533A (https=)
SG (1) SG11202003323TA (https=)
TW (1) TW201934119A (https=)
WO (1) WO2019105972A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020271352A1 (en) * 2019-04-11 2021-10-07 Bayer Aktiengesellschaft Combinations of anti-ILDR2 antibodies and PD-1 antagonists
CN111558038B (zh) * 2020-05-27 2022-04-19 北京加美康联健康管理集团有限公司 一种用于癌症治疗的免疫检查点抑制剂
CN111574626B (zh) * 2020-05-27 2021-12-31 斯爱玲 一种ildr2抗体、其药物组合物及其用途
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
CA3191387A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2009032845A2 (en) * 2007-09-04 2009-03-12 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US20130209463A1 (en) * 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
KR20140126357A (ko) * 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
US20170233473A1 (en) 2014-05-27 2017-08-17 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
KR102399277B1 (ko) 2014-04-10 2022-05-18 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
EP3349794A4 (en) 2015-09-16 2019-07-31 Ablexis, LLC Anti-cd115 antibodies

Also Published As

Publication number Publication date
JP2021504404A (ja) 2021-02-15
PE20200956A1 (es) 2020-09-24
EP3717007A1 (en) 2020-10-07
CA3083675A1 (en) 2019-06-06
BR112020010767A2 (pt) 2020-11-24
JP7350740B2 (ja) 2023-09-26
CN111655287B (zh) 2024-12-27
SG11202003323TA (en) 2020-05-28
AU2018376231A1 (en) 2020-05-07
IL274751B1 (en) 2024-07-01
US11655297B2 (en) 2023-05-23
TW201934119A (zh) 2019-09-01
WO2019105972A1 (en) 2019-06-06
US20200369769A1 (en) 2020-11-26
MX2020005483A (es) 2020-08-27
KR20200096223A (ko) 2020-08-11
EP3717007B1 (en) 2025-09-17
EP3717007C0 (en) 2025-09-17
IL274751A (en) 2020-07-30
CN111655287A (zh) 2020-09-11
AR113850A1 (es) 2020-06-17
IL274751B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
RU2020121533A (ru) Антагонисты ildr2 и их комбинации
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
AU2011325134B2 (en) Methods of treating rheumatoid arthritis using IL-17 antagonists
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
US11795216B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
Palma et al. Mast cell modulation of B cell responses: an under-appreciated partnership in host defence
RU2018111205A (ru) Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
AR035402A1 (es) Anticuerpos humanizados 3d6 y 10d5 o fragmentos de los mismos que reconocen el peptido amiloideo beta, polipeptidos aislados, variantes de los mismos, una molecula de acido nucleico aislada, un vector, una celula portadora, un metodo para producir anticuerpo o fragmento de los mismos, un metodo para
JP2014502955A5 (https=)
JP2019532023A (ja) ヒト抗体、医薬組成物及び方法
TR201802387T4 (tr) Romatoid artritin tedavisine yönelik bileşimler ve bunun kullanımının yöntemleri.
JP2021504404A5 (https=)
KR20200010609A (ko) 종양성 질병들에 대한 치료
AU2015355150A1 (en) Methods for treating dry eye disease by administering an IL-6R antagonist
EA202190495A1 (ru) Антитела против pd-l1 человека
CN114206442A (zh) 用于治疗幼年特发性关节炎的抗il-6受体抗体
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
US20240417473A1 (en) Lag-3 antagonist therapy for hematological cancer
EP3548082B1 (en) A pharmaceutical composition for averting opioid addiction
EP3833687A1 (en) A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
RU2021132572A (ru) Комбинации анти-ildr2 антител и антагонистов pd-1
KR20210106197A (ko) EGFR과 Her2 발현 암세포를 타겟으로 하는 항체-약물 중합체 개발
Higgins et al. Dynamic hinge-motion of PfRIPR revealed by malaria invasion inhibitory antibodies
CN121693348A (zh) 肿瘤联合治疗及使用方法
HK40062612A (en) Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics